Dong Liu1, David R Gibb1,2, Vicente Escamilla-Rivera1, Jingchun Liu1, Manjula Santhanakrishnan1, Zhimin Shi1,3, Lan Xu1, Stephanie C Eisenbarth1,4, Jeanne E Hendrickson1,5. 1. Department of Laboratory Medicine, Yale University School of Medicine, New Haven, Connecticut. 2. Department of Pathology and Laboratory Medicine, Division of Transfusion Medicine, Cedars-Sinai Medical Center, Los Angeles, California. 3. Department of Primary Care, Nanfang Hospital of Southern Medical University, Guangzhou, China. 4. Department of Immunobiology, Yale University School of Medicine, New Haven, Connecticut. 5. Department of Pediatrics, Yale University School of Medicine, New Haven, Connecticut.
Abstract
BACKGROUND: Only a fraction of red blood cell (RBC) transfusion recipients form alloantibodies, and variables determining responsiveness or nonresponsiveness are poorly understood. We and others have previously shown in animal models that pretreatment with toll-like receptor agonists that mimic different types of infections impacts the magnitude or frequency of RBC alloantibody responses. We hypothesized that influenza infection, coexistent with transfusion, would impact responses to transfused RBCs in a manner dependent on Type 1(α/β) interferon (IFN) signaling and tested this in a murine model. STUDY DESIGN AND METHODS: Wild-type mice or mice lacking the ability to respond to Type 1 IFN were infected with influenza prior to the transfusion of transgenic murine RBCs (K1) expressing the human KEL glycoprotein or the triple fusion HOD protein. Alloantibody responses were measured longitudinally after transfusion by flow cytometric crossmatch, and posttransfusion RBC recovery and survival was evaluated. RESULTS: Influenza-infected mice transfused with K1 RBCs developed robust anti-KEL alloantibodies, whereas animals transfused in the absence of infection remained nonresponders; influenza-associated RBC alloimmunization was also observed after transfusion of HOD RBCs. Recipient Type 1 IFN production was critical to the mechanism of action of influenza-induced RBC alloimmunization, with alloimmunization being significantly decreased in mice unable to sense Type 1 IFN (through antibody blockade or genetic approaches). CONCLUSION: These and other data suggest that Type 1 IFN responses to toll-like receptor agonists or infections regulate RBC alloantibody responses. Studies investigating whether such a correlation exists in humans may be informative.
BACKGROUND: Only a fraction of red blood cell (RBC) transfusion recipients form alloantibodies, and variables determining responsiveness or nonresponsiveness are poorly understood. We and others have previously shown in animal models that pretreatment with toll-like receptor agonists that mimic different types of infections impacts the magnitude or frequency of RBC alloantibody responses. We hypothesized that influenza infection, coexistent with transfusion, would impact responses to transfused RBCs in a manner dependent on Type 1(α/β) interferon (IFN) signaling and tested this in a murine model. STUDY DESIGN AND METHODS: Wild-type mice or mice lacking the ability to respond to Type 1 IFN were infected with influenza prior to the transfusion of transgenic murine RBCs (K1) expressing the humanKEL glycoprotein or the triple fusion HOD protein. Alloantibody responses were measured longitudinally after transfusion by flow cytometric crossmatch, and posttransfusion RBC recovery and survival was evaluated. RESULTS:Influenza-infectedmice transfused with K1 RBCs developed robust anti-KEL alloantibodies, whereas animals transfused in the absence of infection remained nonresponders; influenza-associated RBC alloimmunization was also observed after transfusion of HOD RBCs. Recipient Type 1 IFN production was critical to the mechanism of action of influenza-induced RBC alloimmunization, with alloimmunization being significantly decreased in mice unable to sense Type 1 IFN (through antibody blockade or genetic approaches). CONCLUSION: These and other data suggest that Type 1 IFN responses to toll-like receptor agonists or infections regulate RBC alloantibody responses. Studies investigating whether such a correlation exists in humans may be informative.
Authors: David R Gibb; Jingchun Liu; Prabitha Natarajan; Manjula Santhanakrishnan; David J Madrid; Stephanie C Eisenbarth; James C Zimring; Akiko Iwasaki; Jeanne E Hendrickson Journal: J Immunol Date: 2017-06-19 Impact factor: 5.422
Authors: Amal A Al-Garawi; Ramzi Fattouh; Tina D Walker; Erin B Jamula; Fernando Botelho; Susanna Goncharova; Jennifer Reed; Martin R Stampfli; Paul M O'Byrne; Anthony J Coyle; Manel Jordana Journal: J Immunol Date: 2009-03-01 Impact factor: 5.422
Authors: Ross M Fasano; Garrett S Booth; Megan Miles; Liping Du; Tatsuki Koyama; Emily Riehm Meier; Naomi L C Luban Journal: Br J Haematol Date: 2014-09-26 Impact factor: 6.998
Authors: Elizabeth B Wilson; Douglas H Yamada; Heidi Elsaesser; Jonathan Herskovitz; Jane Deng; Genhong Cheng; Bruce J Aronow; Christopher L Karp; David G Brooks Journal: Science Date: 2013-04-12 Impact factor: 47.728
Authors: Samuele Calabro; Antonia Gallman; Uthaman Gowthaman; Dong Liu; Pei Chen; Jingchun Liu; Jayendra Kumar Krishnaswamy; Manuela Sales L Nascimento; Lan Xu; Seema R Patel; Adam Williams; Christopher A Tormey; Eldad A Hod; Steven L Spitalnik; James C Zimring; Jeanne E Hendrickson; Sean R Stowell; Stephanie C Eisenbarth Journal: J Exp Med Date: 2016-05-16 Impact factor: 14.307
Authors: Deepak Singhal; Monika M Kutyna; Rakchha Chhetri; Li Yan A Wee; Sophia Hague; Lakshmi Nath; Shriram V Nath; Romi Sinha; Nicholas Wickham; Ian D Lewis; David M Ross; Peter G Bardy; Luen Bik To; John Reynolds; Erica M Wood; David J Roxby; Devendra K Hiwase Journal: Haematologica Date: 2017-10-05 Impact factor: 9.941
Authors: Arijita Jash; Chomkan Usaneerungrueng; Heather L Howie; Annie Qiu; Chance John Luckey; James C Zimring; Krystalyn E Hudson Journal: Front Immunol Date: 2021-03-12 Impact factor: 7.561
Authors: Emaan Madany; June Lee; Chelsea Halprin; Jina Seo; Nicole Baca; Fataneh Majlessipour; Jeanne E Hendrickson; Samuel H Pepkowitz; Chelsea Hayes; Ellen Klapper; David R Gibb Journal: EJHaem Date: 2021-07-27
Authors: Vicente Escamilla-Rivera; Jingchun Liu; David R Gibb; Manjula Santhanakrishnan; Dong Liu; James E Forsmo; Stephanie C Eisenbarth; Ellen F Foxman; Sean R Stowell; Chance John Luckey; James C Zimring; Krystalyn E Hudson; Jeanne E Hendrickson Journal: Blood Date: 2020-05-28 Impact factor: 25.476
Authors: June Young Lee; Emaan Madany; Najwa El Kadi; Sumaarg Pandya; Kessandra Ng; Michifumi Yamashita; Caroline A Jefferies; David R Gibb Journal: Front Immunol Date: 2020-09-25 Impact factor: 7.561